Impact of Nebivolol on Central Aortic Pressure

This study has been withdrawn prior to enrollment.
(Similar study already published)
Sponsor:
Information provided by:
Creighton University
ClinicalTrials.gov Identifier:
NCT01051947
First received: January 19, 2010
Last updated: July 29, 2011
Last verified: July 2011
  Purpose

A randomized, cross-over, single-blind study to compare the effects of nebivolol and metoprolol on central aortic pressure and peripheral brachial pressure in patients with stable cardiovascular disease.


Condition Intervention
Central Aortic Pressure
Drug: Nebivolol
Drug: Metoprolol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Impact of Nebivolol on Central Aortic Pressure

Resource links provided by NLM:


Further study details as provided by Creighton University:

Primary Outcome Measures:
  • Stable blood pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Subjects will be randomized to nebivolol or metoprolol. Their medication will be titrated so that their blood pressure is within 10% of their initial reading.


Enrollment: 0
Study Start Date: December 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nebivolol
Nebivolol therapy for 2-6 weeks depending on blood pressure readings
Drug: Nebivolol
10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
Experimental: Metoprolol
Metoprolol therapy for 2-6 weeks depending on blood pressure readings
Drug: Metoprolol
dosage prescribed prior to starting on study

  Eligibility

Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with history of hypertension
  • Subjects who have received metoprolol for a minimum of 3 months

Exclusion Criteria:

  • Patients who have had an acute myocardial infarction, coronary revascularization or who have been hospitalized for heart failure or cardiac arrhythmia in the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01051947

Locations
United States, Nebraska
The Cardiac Center at Creighton University
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Creighton University
Investigators
Principal Investigator: Jennifer Campbell, PharmD Creighton University
  More Information

No publications provided

Responsible Party: Jennifer Campbell, PharmD, Creighton University
ClinicalTrials.gov Identifier: NCT01051947     History of Changes
Other Study ID Numbers: 08-15168
Study First Received: January 19, 2010
Last Updated: July 29, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Creighton University:
Nebivolol
Metoprolol
central aortic pressure
hypertension

Additional relevant MeSH terms:
Metoprolol
Nebivolol
Metoprolol succinate
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents

ClinicalTrials.gov processed this record on August 20, 2014